People with reduced kidney function may have higher levels of several blood markers commonly used in Alzheimer’s disease ...
A lifelong Millwall fan has selflessly donated one of his kidneys to a Crystal Palace supporter, who says he woke ...
Abstract: Chronical kidney diseases commonly known as chronic renal illness, is a kind of Kidney disease is characterized by abnormal kidneys function or breakdown of renal function that takes a long ...
Novartis announced final results from the phase III ALIGN study supporting a slowing decline in kidney function in adults with IgA nephropathy (IgAN) who were treated with Vanrafia (atrasentan).
Identifying population-based eGFR distributions may help to identify patients at risk for developing chronic kidney disease earlier, according to study data published in Kidney International. More ...
Long-term data from the phase 3 ALIGN trial reinforce the safety and efficacy of atrasentan for patients with immunoglobulin A nephropathy.
Novartis to seek full FDA approval for IgAN drug Vanrafia despite missing ph. 3 kidney function goal
It’s déjà vu all over again. Just as the kidney disease space becomes increasingly competitive, Novartis has found itself intending to turn a statistical miss into a regulatory win. | It’s déjà vu all ...
His CT, EEG and MRI were negative. He had been taking gabapentin for four years with a current dosage of 1,800 mg daily. When this was stopped, he immediately began regaining his cognition and was ...
Noninvasive ultrasound localization microscopy-based assessment of intrarenal microvasculature can reveal microvascular abnormalities at an early stage in individuals with polycystic kidney disease.
Biologically optimised plasma p-tau217 cutoffs improve amyloid beta detection accuracy and cost efficiency. Learn more about ...
Novartis announced that its investigational drug Vanrafia has successfully demonstrated the ability to slow kidney function decline in adults living with IgA nephropathy (IgAN), a chronic and ...
Investing.com -- Novartis announced Friday that its drug Vanrafia has demonstrated effectiveness in slowing the decline of kidney function in adults with IgA nephropathy (IgAN), a progressive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results